Company intelligence / Profile preview

Galacticat

Ownership: Private
Employees: ~9
Development stage: Other

Overview

Galactica Biotech applies advanced analytical methods including machine learning to identify new uses for existing molecules. Their platform has identified potential active molecules against COVID‑19, but there are no reported clinical results or ongoing trials. The company specializes in drug repurposing, virtual screening, and target identification to accelerate pharmaceutical R&D.

Therapeutic areas: OncologyRare DiseasesInfectious Diseases
Modalities: Small moleculePossibly biologics
Industry: Drug Discovery Services

Beyond the preview

Go deeper on Galacticat.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Galacticat.

Explore the full profile